Physician profile
Dean Alan Edwards
NPI 1487624557
$2,593.25
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $48.99 · 2021: $448 · 2022: $700 · 2023: $746 · 2024: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $395.24 | 2019-2024 | Skyrizi, Rinvoq, Linzess |
| Daiichi Sankyo INC. | $295.57 | 2019-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.72 | 2021-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $253.69 | 2021-2024 | Stelara, Remicade, Simponi Aria |
| Genzyme Corporation | $230.13 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $200.78 | 2019-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $156.38 | 2019-2024 | Entyvio |
| Ironwood Pharmaceuticals, INC | $137.34 | 2019-2023 | Linzess |
| Pfizer INC. | $96.20 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $86.15 | 2019-2023 | Rebyota |
| Celgene Corporation | $84.48 | 2023-2024 | Zeposia |
| Ucb, INC. | $73.83 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $52.53 | 2023 | Dupixent |
| Braintree Laboratories, INC. | $46.34 | 2022-2023 | Sutab |
| Redhill Biopharma INC. | $40.56 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $29.77 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $20.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $17.04 | 2024 | Voquezna |
| Boston Scientific Corporation | $16.47 | 2024 | Compliance Endokit |
| Intercept Pharmaceuticals, INC. | $16.06 | 2024 | |
| Qol Medical, LLC | $15.02 | 2019 | |
| Amgen INC. | $14.66 | 2022 | |
| Fresenius Kabi USA, LLC | $13.24 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.